News Sentiment

ZBIO sentiment intelligence

Zenas BioPharma, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 72 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 28.74 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+5.5% over one week, +45.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise (NASDAQ:ZBIO)

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 5.5% Price confirming higher
Trend fit Trend inactive 45.2% over four weeks
Fair value 58.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 47
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingView 8
Market source 7
The National Law Review 6
TradingKey 4
GlobeNewswire 4
simplywall.st 3
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 18
Regulatory and legal 8
Balance sheet 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 72
Stock Titan Direct company coverage

Zenas BioPharma (ZBIO) director awarded 500K stock options at $18.71

Zenas BioPharma (ZBIO) director Leon O. Moulder Jr. was granted 500,000 stock options with an exercise price of $18.71 per share, expiring on June 15, 2036. The options will vest 25% on June 15, 2027, with the remaining shares vesting monthly over 36 months, subject to continued

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:09
Source
Stock Titan
TradingKey Direct company coverage

Zenas Biopharma Inc (ZBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Zenas Biopharma Inc (ZBIO), listing its major shareholders and institutional holdings as of recent updates. Key shareholders include Fidelity Management & Research Company LLC, SR One Capital Management, LP, and InnoCare Pharma In

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:09
Source
TradingKey
Stock Titan Direct company coverage

Director at Zenas BioPharma (ZBIO) receives 18,500 stock options grant

Zenas BioPharma (ZBIO) director Patricia L. Allen was granted stock options for 18,500 shares. The options have an exercise price of $18.71 per share and will expire on June 15, 2036. They vest fully on June 15, 2027, provided her service continues.

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

Zenas BioPharma (ZBIO) awards options and ESPP shares to officer

Zenas BioPharma (ZBIO) officer Jennifer A. Fox received 125,000 stock options at an exercise price of $18.71, expiring in 2036. She also acquired 1,592 common shares at $13.35 through the company's 2024 Employee Stock Purchase Plan. The options have a vesting schedule over 36 mon

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 22:09
Source
Stock Titan
TradingView Direct company coverage

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Zenas Biopharma announced inducement grants made in accordance with Nasdaq Listing Rule 5635(C)(4). The grants are part of the company's compliance with Nasdaq's regulatory framework. This brief announcement was distributed via Reuters and Refinitiv.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
17 Jun 2026 20:09
Source
TradingView